CFS
MCID: CHR066
MIFTS: 58

Chronic Fatigue Syndrome (CFS)

Categories: Mental diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Chronic Fatigue Syndrome

MalaCards integrated aliases for Chronic Fatigue Syndrome:

Name: Chronic Fatigue Syndrome 11 75 53 41 14 16 71 33
Postviral Fatigue Syndrome 11 31 33
Myalgic Encephalomyelitis 11 75 33
Cfs 11 14
Pvfs - [postviral Fatigue Syndrome] 33
Myalgic Encephalomyelitis Syndrome 33
Benign Myalgic Encephalomyelitis 33
Cfs - [chronic Fatigue Syndrome] 33
Me - [myalgic Encephalomyelitis] 33
Encephalomyelitis, Myalgic 75
Fatigue Syndrome, Chronic 43
Epidemic Neuromyasthenia 33
Myalgic Encephalitis 11
Icelandic Disease 33
Akureyri Disease 33
Chronic Fatigue 5
Neuromyasthenia 33
Iceland Disease 33
Akureyri 33

Classifications:



External Ids:

Disease Ontology 11 DOID:8544
ICD9CM 34 780.71
MeSH 43 D015673
NCIt 49 C3037
SNOMED-CT 68 193054000
ICD10 31 G93.3
ICD11 33 569175314
UMLS 71 C0015674

Summaries for Chronic Fatigue Syndrome

MedlinePlus: 41 What is chronic fatigue syndrome (CFS)? Chronic fatigue syndrome (CFS) is a serious, long-term illness that affects many body systems. Another name for it is myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). CFS can often make you unable to do your usual activities. Sometimes you may not even be able to get out of bed. What causes chronic fatigue syndrome (CFS)? The cause of CFS is unknown. There may be more than one thing that causes it. It is possible that two or more triggers might work together to cause the illness. Who is at risk for chronic fatigue syndrome (CFS)? Anyone can get CFS, but it is most common in people between 40 and 60 years old. Adult women have it more often that adult men. Whites are more likely than other races to get a diagnosis of CFS, but many people with CFS have not been diagnosed with it. What are the symptoms of chronic fatigue syndrome (CFS)? CFS symptoms can include: Severe fatigue that is not improved by rest Sleep problems Post-exertional malaise (PEM), where your symptoms get worse after any physical or mental activity Problems with thinking and concentrating Pain Dizziness CFS can be unpredictable. Your symptoms may come and go. They may change over time - sometimes they might get better, and other times they may get worse. How is chronic fatigue syndrome (CFS) diagnosed? CFS can be difficult to diagnose. There is no specific test for CFS, and other illnesses can cause similar symptoms. Your health care provider has to rule out other diseases before making a diagnosis of CFS. He or she will do a thorough medical exam, including: Asking about your medical history and your family's medical history Asking about your current illness, including your symptoms. Your doctor will want to know how often you have symptoms, how bad they are, how long they have lasted, and how they affect your life. A thorough physical and mental status exam Blood, urine, or other tests What are the treatments for chronic fatigue syndrome (CFS)? There is no cure or approved treatment for CFS, but you may be able to treat or manage some of your symptoms. You, your family, and your health care provider should work together to decide on a plan. You should figure out which symptom causes the most problems and try to treat that first. For example, if sleep problems affect you the most, you might first try using good sleep habits. If those do not help, you may need to take medicines or see a sleep specialist. Strategies such as learning new ways to manage activity can also be helpful. You need to make sure that you do not "push and crash." This can happen when you feel better, do too much, and then get worse again. Since the process of developing a treatment plan and attending to self-care can be hard if you have CFS, it is important to have support from family members and friends. Don't try any new treatments without talking to your health care provider. Some treatments that are promoted as cures for CFS are unproven, often costly, and could be dangerous. Centers for Disease Control and Prevention

MalaCards based summary: Chronic Fatigue Syndrome, also known as postviral fatigue syndrome, is related to irritable bowel syndrome and fibromyalgia, and has symptoms including muscle weakness, fatigue and fever. An important gene associated with Chronic Fatigue Syndrome is RNASEL (Ribonuclease L), and among its related pathways/superpathways are Signal Transduction and TGF-Beta Pathway. The drugs Ethanol and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and breast, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Disease Ontology: 11 A syndrome that involves prolonged and severe tiredness or weariness that is unrelated to exertion, is not relieved by rest and for a minimum of six months and is not directly caused by other conditions.

Wikipedia: 75 Chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME) or ME/CFS, is a complex,... more...

Related Diseases for Chronic Fatigue Syndrome

Diseases related to Chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 833)
# Related Disease Score Top Affiliating Genes
1 irritable bowel syndrome 32.1 VIP SLC6A4 POMC IL6 HTR1A CRH
2 fibromyalgia 31.9 SLC6A4 POMC MAOA INS IL6 IGF1
3 viral infectious disease 31.6 RNASEL IL6 IL2 IFNG EIF2AK2
4 personality disorder 31.4 SLC6A4 NR3C1 MAOA HTR1A CRH
5 sleep disorder 31.4 SLC6A4 POMC INS IL6 IGF1 HTR1A
6 autoimmune disease 31.3 MIR146A INS IL6 IL2 IFNG
7 somatization disorder 31.2 SLC6A4 POMC IL6 CRH
8 premature ovarian failure 7 31.2 POMC GH1 CRH
9 apnea, obstructive sleep 31.2 POMC INS IL6 IGF1
10 paine syndrome 31.1 SLC6A4 POMC IL6 CRH
11 mood disorder 31.1 SLC6A4 POMC NR3C1 MAOA IL6 HTR1A
12 major depressive disorder 31.1 SLC6A4 POMC NR3C1 MAOA INS IL6
13 sleep apnea 31.0 SLC6A4 INS IL6 IGF1
14 anxiety 31.0 SLC6A4 POMC NR3C1 MAOA INS IL6
15 poliomyelitis 31.0 IL6 IL2 IFNG
16 acute stress disorder 30.9 SLC6A4 POMC NR3C1 CRH
17 chickenpox 30.9 IL6 IL2 IFNG
18 generalized anxiety disorder 30.9 SLC6A4 POMC MAOA IL6 HTR1A CRH
19 leptin deficiency or dysfunction 30.9 POMC INS IL6 IGF1 CRH
20 panic disorder 30.9 SLC6A4 POMC MAOA IL6 HTR1A CRH
21 rhinitis 30.9 VIP POMC NR3C1 IL6 IFNG
22 neurotic disorder 30.8 SLC6A4 POMC MAOA INS IL6 HTR1A
23 somatoform disorder 30.8 SLC6A4 POMC IL6 HTR1A CRH
24 hypochondriasis 30.8 SLC6A4 POMC MAOA HTR1A
25 dysthymic disorder 30.8 SLC6A4 POMC MAOA INS IL6 HTR1A
26 endogenous depression 30.8 SLC6A4 POMC NR3C1 MAOA INS IL6
27 celiac disease 1 30.8 INS IL6 IL2 IGF1 IFNG
28 post-traumatic stress disorder 30.7 SLC6A4 POMC NR3C1 MAOA IL6 HTR1A
29 amenorrhea 30.7 POMC INS IGF1 CRH
30 immune deficiency disease 30.7 RNASEL MIR146A INS IL6 IL2 IFNG
31 hypothyroidism 30.7 POMC INS IL2 IGF1 GH1
32 hypoglycemia 30.7 POMC NR3C1 INS IGFBP1 IGF2 IGF1
33 insulin-like growth factor i 30.7 INS IL6 IGFBP1 IGF2 IGF1 GH1
34 brucellosis 30.7 IL6 IL2 IFNG
35 thyroiditis 30.7 INS IL6 IL2 IFNG
36 connective tissue disease 30.7 MIR146A INS IL6 IL2 IGF1 IFNG
37 severe acute respiratory syndrome 30.7 IL6 IL2 IFNG
38 erythema multiforme 30.6 IL6 IL2 IFNG
39 persian gulf syndrome 30.6 VIP ADCYAP1
40 deficiency anemia 30.6 INS IL6 IL2 IGF1 GH1
41 exanthem 30.6 IL6 IL2 IFNG
42 rheumatoid arthritis 30.6 NR3C1 MIR146A IL6 IL2 IFNG CRH
43 primary biliary cholangitis 30.6 SUN2 INS IL6 IL2
44 agoraphobia 30.6 SLC6A4 MAOA HTR1A CRH
45 migraine with or without aura 1 30.5 VIP SLC6A4 POMC MAOA INS IL6
46 stomatitis 30.5 IL6 IL2 IFNG EIF2AK2
47 proteasome-associated autoinflammatory syndrome 1 30.5 INS IL6 IFNG
48 eating disorder 30.5 SLC6A4 POMC INS IGF1 HTR1A CRH
49 hypokalemia 30.5 VIP POMC NR3C1 INS CRH
50 psychotic disorder 30.5 SLC6A4 MIR146A MAOA INS IL6 HTR1A

Graphical network of the top 20 diseases related to Chronic Fatigue Syndrome:



Diseases related to Chronic Fatigue Syndrome

Symptoms & Phenotypes for Chronic Fatigue Syndrome

UMLS symptoms related to Chronic Fatigue Syndrome:


muscle weakness; fatigue; fever; back pain; myalgia; pruritus; sciatica; muscle cramp; muscle rigidity; muscle spasticity; (non-specific) malaise and fatigue; other malaise and fatigue

GenomeRNAi Phenotypes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ADCYAP1 EIF2AK2 IGF1 IGF2 MAOA NR3C1

MGI Mouse Phenotypes related to Chronic Fatigue Syndrome:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.46 ADCYAP1 CRH EIF2AK2 GH1 HTR1A IFNG
2 nervous system MP:0003631 10.41 ADCYAP1 CRH GH1 HTR1A IFNG IGF1
3 growth/size/body region MP:0005378 10.37 ADCYAP1 CRH EIF2AK2 GH1 IFNG IGF1
4 cellular MP:0005384 10.33 ADCYAP1 CRH EIF2AK2 IFNG IGF1 IGF2
5 immune system MP:0005387 10.3 ADCYAP1 CRH EIF2AK2 GH1 IFNG IGF1
6 endocrine/exocrine gland MP:0005379 10.29 CRH GH1 IFNG IGF1 IGF2 IL2
7 liver/biliary system MP:0005370 10.28 ADCYAP1 CRH GH1 IFNG IGF2 IGFBP1
8 behavior/neurological MP:0005386 10.28 ADCYAP1 CRH GH1 HTR1A IFNG IGF2
9 no phenotypic analysis MP:0003012 10.27 ADCYAP1 CRH HTR1A IFNG IGF2 IL2
10 cardiovascular system MP:0005385 10.25 GH1 HTR1A IFNG IGF1 IGF2 IL2
11 renal/urinary system MP:0005367 10.21 CRH GH1 IFNG IGF1 IGF2 IL6
12 muscle MP:0005369 10.2 ADCYAP1 IFNG IGF1 IGF2 IL6 INS
13 neoplasm MP:0002006 10.13 EIF2AK2 IFNG IGF1 IL2 IL6 MIR146A
14 adipose tissue MP:0005375 10.13 ADCYAP1 CRH GH1 IGF1 IL6 INS
15 hematopoietic system MP:0005397 10.03 ADCYAP1 CRH EIF2AK2 GH1 IFNG IGF1
16 reproductive system MP:0005389 10 ADCYAP1 GH1 IFNG IGF1 IGF2 IL2
17 respiratory system MP:0005388 9.97 CRH GH1 IFNG IGF1 IGF2 IL2
18 mortality/aging MP:0010768 9.89 ADCYAP1 EIF2AK2 GH1 HTR1A IFNG IGF1
19 integument MP:0010771 9.32 CRH IFNG IGF1 IGF2 IL6 INS

Drugs & Therapeutics for Chronic Fatigue Syndrome

Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
3
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
4
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
5
Tetracycline Approved, Vet_approved, Withdrawn Phase 4 60-54-8 5353990
6
Sodium oxybate Approved Phase 4 502-85-2 23663870
7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
8
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
9
Garlic Approved, Nutraceutical Phase 4 8008-99-9
10
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
12
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
13 Antioxidants Phase 4
14 Protective Agents Phase 4
15
Ginkgo Phase 4
16 Allyl sulfide Phase 4
17 Lemon Balm Phase 4
18 Hawthorn Phase 4
19 Diallyl Sulfide Phase 4
20 Anti-Infective Agents Phase 4
21 Central Nervous System Stimulants Phase 4
22 Dopamine Uptake Inhibitors Phase 4
23 Vasodilator Agents Phase 4
24 Phosphodiesterase Inhibitors Phase 4
25 Phosphodiesterase 5 Inhibitors Phase 4
26 Citrate Phase 4
27
Lisdexamfetamine Dimesylate Phase 4
28 Liver Extracts Phase 4
29 Anti-Bacterial Agents Phase 4
30 Antiprotozoal Agents Phase 4
31 Antiparasitic Agents Phase 4
32 Antimalarials Phase 4
33 Antibiotics, Antitubercular Phase 4
34 Immunologic Factors Phase 4
35 Immunosuppressive Agents Phase 4
36 Complement System Proteins Phase 4
37 Complement C1s Phase 4
38 Complement C1 Inhibitor Protein Phase 4
39 Complement C1 Inactivator Proteins Phase 4
40 Vitamins Phase 4
41 Folate Phase 4
42 Vitamin B9 Phase 4
43 Trace Elements Phase 4
44 Vitamin B Complex Phase 4
45 Micronutrients Phase 4
46 Vitamin B1 Phase 4
47 Thiamin Phase 4
48 Anesthetics, Intravenous Phase 4
49 Anesthetics, General Phase 4
50 Anesthetics Phase 4

Interventional clinical trials:

(show top 50) (show all 185)
# Name Status NCT ID Phase Drugs
1 The Effect of Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
2 The Effect of Nasal CPAP in Patients With Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
3 High-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage in Chronic Fatigue Patients: Randomized-controlled Study Unknown status NCT01926132 Phase 4 ascorbic acid 10g/20ml;Normal Saline 150ml
4 A Placebo-controlled, Randomized, Double-blind, Parallel, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation Unknown status NCT03542721 Phase 4 DA-5515;Placebo of DA-5515
5 Chronic Fatigue Syndrome and Abdominal Symptoms After Giardia Infection: Clinical Evaluation, Biomarkers, Risk Factors and the Effect of Intervention Completed NCT00860236 Phase 4
6 Slow-wave Sleep and Daytime Functioning in Chronic Fatigue Syndrome: Effects of Sodium Oxybate Completed NCT02055898 Phase 4 Sodium Oxybate
7 Phase 4 Study of the Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With Chronic Fatigue Syndrome. Completed NCT00598585 Phase 4 Sildenafil (Viagra);Placebo
8 Use of Lisdexamfetamine Dimesylate in Treatment of Cognitive Impairment (Chronic Fatigue Syndrome): A Double Blind, Placebo Controlled Study Completed NCT01071044 Phase 4 Lisdexamfetamine Dimesylate;Placebo "30, 50 or 70 mg"
9 The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment Completed NCT01318356 Phase 4 Doxycycline;Placebo
10 A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection Recruiting NCT04705831 Phase 4 Ruconest
11 PBC Induced Fatigue Treated With Thiamine (PIFT) - The Effect of Oral Thiamine Supplement in 4 Weeks to Patients With Primary Biliary Cholangitis (PBC) and Chronic Fatigue. A Randomised Placebo Controlled Crossover Study Recruiting NCT04893993 Phase 4 Thiamine;Placebo
12 A Double-Blind, Randomized, Placebo-Controlled, Single-Center, Flexible Titration Study Evaluating the Efficacy of Solriamfetol in Treating Fatigue and Cognitive Symptoms in Adults Aged 18-65 Years With a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not yet recruiting NCT04622293 Phase 4 Solriamfetol Oral Tablet [Sunosi];Placebo
13 Post-COVID-19 Chronic Fatigue Syndrome Not yet recruiting NCT05642923 Phase 4 Synthetic Vitamin B1
14 Phase IV - A Trial of Xyrem in the Treatment of Chronic Fatigue Syndrome. Terminated NCT00498485 Phase 4 Placebo;Sodium Oxybate
15 Clinical Trial, Randomized, Controlled, Parallel, to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With Chronic Fatigue Syndrome. Unknown status NCT01907711 Phase 2, Phase 3
16 A Randomized, Placebo-Controlled, Double-Blind Trial of Duloxetine in the Treatment of Patients With Chronic Fatigue Syndrome Completed NCT00375973 Phase 2, Phase 3 Duloxetine;Placebo
17 Cytokine Inhibition in Chronic Fatigue Syndrome Patients Completed NCT02108210 Phase 2, Phase 3 Anakinra;Placebo
18 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-blind, Placebo-controlled Study. Completed NCT00848692 Phase 2, Phase 3 Rituximab;Saline (NaCl 0,9 %) (placebo)
19 A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME) Completed NCT00215800 Phase 3 Ampligen
20 B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment. Completed NCT02229942 Phase 3 Rituximab;Placebo
21 Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Clinical Study to Explore the Efficacy and Safety of GCJBP Laennec Inj.(Human Placenta Hydrolysate) 4ml Per Day 3 Times Per Week for 6 Weeks in the Chronic Fatigue Patients With Chronic Fatigue Syndrome or Idiopathic Chronic Fatigue Completed NCT01742013 Phase 3 GCJBP Laennec Inj.;Placebo
22 A Randomized, Double-blind, Placebo-controlled, Comparative Clinical Trial to Measure the Maximun Heart Rate During a Cycle Ergometer Test After ReConnect® Supplementation in CFS. Completed NCT02063126 Phase 2, Phase 3
23 Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors Completed NCT01281904 Phase 2, Phase 3
24 A Randomized, Double-blind Placebo-controlled Phase III Trial of Coenzyme Q10 in Gulf War Illness Completed NCT02865460 Phase 3 Ubiquinol;Placebo
25 The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis. Completed NCT02315872 Phase 3 ACTH;Placebo
26 Adjunctive Treatment With Pramipexole for Anhedonic Depression Symptoms in Depression - PRIME-PRAXOL Not yet recruiting NCT05355337 Phase 3 Pramipexole;Placebo
27 Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Methylphenidate Hydrochloride as a Treatment for Chronic Fatigue Syndrome in Patients Taking a CFS-Specific Nutrient Formula Unknown status NCT01966276 Phase 2 Methyl-P plus Nutrient Formula;Methyl-P plus Nutrient matched placebos
28 Phase 1 + 2a Proof of Concept Study of Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®) Unknown status NCT01793415 Phase 1, Phase 2 IodoCarb (r)
29 High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome - A Sino-Austrian Cooperation Randomized Controlled Trial(RCT) on Heart Rate Variability Unknown status NCT02924831 Phase 2
30 Effects of Iron Therapy in Patients With Chronic Fatigue and IBD Unknown status NCT02517151 Phase 2 Ferric carboxymaltose;Placebo
31 The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Completed NCT03674541 Phase 2 Pyridostigmine Bromide;Placebo
32 Behavioral Insomnia Therapy With Chronic Fatigue Syndrome Completed NCT00540254 Phase 1, Phase 2
33 A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir (Valcyte) in Patients Experiencing Chronic Fatigue Syndrome With Elevated Antibody Titers Against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) Completed NCT00478465 Phase 1, Phase 2 valganciclovir
34 Pilot Phase 1/2, Open-Label, Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Completed NCT03613129 Phase 1, Phase 2 CT38
35 Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS). Part A: an Open Label Phase-II Study With Six Intravenous Cyclophosphamide Infusions Four Weeks Apart, and Follow-up for 12 Months Completed NCT02444091 Phase 2 Cyclophosphamide
36 The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial Completed NCT01040429 Phase 2 Clonidine;Lactose capsula
37 Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome: Randomized Controlled Clinical Trial Completed NCT01512342 Phase 2
38 B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. An Open Label Phase II Study With Rituximab Induction and Maintenance Treatment Completed NCT01156909 Phase 2 Rituximab
39 Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement Recruiting NCT04542161 Phase 2 NAC 900mg/day;NAC 3600mg/day;NAC 0mg/day (Placebo)
40 Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments Recruiting NCT03844412 Phase 2 5% lidocaine/5 mg/ml 0.02% estradiol compound cream;Nortriptyline;Placebo cream;Placebo pill
41 Improving Patient-Important Outcomes With Testosterone Replacement in Hypogonadal Men With a Prior History of Cancer Recruiting NCT04049331 Phase 2 Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]
42 Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis? Recruiting NCT03983720 Phase 2
43 Fecal Microbiota Transplantation in Chronic Fatigue Syndrome - an RCT Active, not recruiting NCT03691987 Phase 2
44 A Double Blind Randomized Trial of Low-dose Naltrexone for Post-COVID Fatigue Syndrome Not yet recruiting NCT05430152 Phase 2 Low-Dose Naltrexone
45 Microbiome Targeted Oral Butyrate Therapy in Gulf War Multisymptom Illness Not yet recruiting NCT05367245 Phase 2 Cal-Mag Butyrate;Placebo
46 An Open-Label Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome Terminated NCT00977171 Phase 2 Droxidopa
47 Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Moderate and Serious Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME), Including in Patients With no Clinical Response After B-lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab. Terminated NCT01730495 Phase 2 Etanercept
48 B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Severely Affected Chronic Fatigue Syndrome Patients. An Open Label Phase II Study With Rituximab Induction and Maintenance Treatment for Patients in WHO Performance Status III-IV Terminated NCT01156922 Phase 2 Rituximab
49 Chronic Fatigue Syndrome: Correction of Mitochondrial Dysfunction by Conditioning Exercise and Nutraceutical Therapy. Withdrawn NCT01471652 Phase 2 Nutraceutical supplements;Placebo
50 Autonomic Nervous System and Chronic Fatigue Syndrome Completed NCT00580619 Phase 1 L-NMMA trimethaphan;methyldopa

Search NIH Clinical Center for Chronic Fatigue Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


coenzyme Q10
Fish Oils
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: fatigue syndrome, chronic

Genetic Tests for Chronic Fatigue Syndrome

Anatomical Context for Chronic Fatigue Syndrome

Organs/tissues related to Chronic Fatigue Syndrome:

MalaCards : Brain, Heart, Breast, Spinal Cord, Amygdala, Placenta, Endothelial

Publications for Chronic Fatigue Syndrome

Articles related to Chronic Fatigue Syndrome:

(show top 50) (show all 8244)
# Title Authors PMID Year
1
Tai Chi increases functional connectivity and decreases chronic fatigue syndrome: A pilot intervention study with machine learning and fMRI analysis. 62 41
36454926 2022
2
Measuring frailty and its association with key outcomes in the ambulance setting: a cross sectional observational study. 41
36471316 2022
3
Development and assessment of an educational intervention to improve the recognition of frailty on an acute care respiratory ward. 41
36454710 2022
4
Glucocorticoid receptor mediated negative feedback in chronic fatigue syndrome using the low dose (0.5 mg) dexamethasone suppression test. 53 62
18573538 2009
5
Combined dexamethasone/corticotropin-releasing factor test in chronic fatigue syndrome. 53 62
17803834 2008
6
Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance. 53 62
18396793 2008
7
[Overlap between atypical depression, seasonal affective disorder and chronic fatigue syndrome]. 53 62
17546343 2007
8
Glucocorticoid receptor polymorphisms and haplotypes associated with chronic fatigue syndrome. 53 62
16740143 2007
9
Inclusion of the glucocorticoid receptor in a hypothalamic pituitary adrenal axis model reveals bistability. 53 62
17300722 2007
10
Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome. 53 62
16277015 2005
11
2',5'-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome. 53 62
15924878 2005
12
Variability of the RNase L isoform ratio (37 kiloDaltons/83 kiloDaltons) in diagnosis of chronic fatigue syndrome. 53 62
15699437 2005
13
Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635. 53 62
15691524 2005
14
Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. 53 62
15710856 2005
15
Do cytosine guanine dinucleotide (CpG) fragments induce vasoactive neuropeptide mediated fatigue-related autoimmune disorders? 53 62
15922114 2005
16
Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression. 53 62
15885924 2005
17
Reduction of serotonin transporters of patients with chronic fatigue syndrome. 53 62
15570154 2004
18
Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome. 53 62
15110921 2004
19
RNase L levels in peripheral blood mononuclear cells: 37-kilodalton/83-kilodalton isoform ratio is a potential test for chronic fatigue syndrome. 53 62
12626460 2003
20
Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. 53 62
12377295 2002
21
Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients. 53 62
12118002 2002
22
Antiviral pathway activation in patients with chronic fatigue syndrome and acute infection. 53 62
11698994 2001
23
Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. 53 62
11502777 2001
24
Increased sensitivity to glucocorticoids in peripheral blood mononuclear cells of chronic fatigue syndrome patients, without evidence for altered density or affinity of glucocorticoid receptors. 53 62
11288761 2001
25
Abnormalities in response to vasopressin infusion in chronic fatigue syndrome. 53 62
11087963 2001
26
A preliminary study of dehydroepiandrosterone response to low-dose ACTH in chronic fatigue syndrome and in healthy subjects. 53 62
11104854 2000
27
A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. 53 62
11030484 2000
28
A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. 53 62
11126321 2000
29
Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. 53 62
10356627 1999
30
Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. 53 62
9669518 1998
31
The low dose ACTH test in chronic fatigue syndrome and in health. 53 62
9713562 1998
32
A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction. 53 62
9576011 1998
33
Fibromyalgia, chronic fatigue syndrome, and myofascial pain. 53 62
9567202 1998
34
Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. 53 62
9243369 1997
35
Changes in growth hormone, insulin, insulinlike growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndrome. 53 62
9046989 1997
36
Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. 53 62
7893988 1994
37
Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. 53 62
8148461 1994
38
The fragile process of Homecoming - Young women in recovery from severe ME/CFS. 62
36367977 2023
39
Subjective and objective cognitive function in adolescent with chronic fatigue following Epstein-Barr virus infection. 62
36327530 2022
40
Can exercise training promote better sleep and reduced fatigue in people with chronic stroke? A systematic review. 62
35762096 2022
41
Correction: Association between school absence and physical function in paediatric chronic fatigue syndrome/myalgic encephalopathy. 62
36351760 2022
42
Response to the report published by the UK House of Commons All-Party Parliamentary Group on Chronic Fatigue Syndrome/Myalgic Encephalitis (CFS/ME): implications for cardiometabolic risk. 62
36168429 2022
43
Severe myalgic encephalomyelitis/chronic fatigue syndrome in children and young people: a British Paediatric Surveillance Unit study. 62
36456114 2022
44
Brain fog of post-COVID-19 condition and Chronic Fatigue Syndrome, same medical disorder? 62
36474290 2022
45
Correction: Depression in paediatric chronic fatigue syndrome. 62
36347570 2022
46
Assessing sleep and pain among adults with myalgic encephalomyelitis/chronic fatigue syndrome: psychometric evaluation of the PROMIS® sleep and pain short forms. 62
35896905 2022
47
The Impact of Micro RNA-320a Serum Level on Severity of Symptoms and Cerebral Processing of Pain in Patients with Fibromyalgia. 62
35587745 2022
48
Protracted stress-induced hypocortisolemia may account for the clinical and immune manifestations of Long COVID. 62
36182048 2022
49
Long Covid at the crossroads: Comparisons and lessons from the treatment of patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). 62
35341334 2022
50
Long COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome: Similarities and differences of two peas in a pod. 62
35693424 2022

Variations for Chronic Fatigue Syndrome

ClinVar genetic disease variations for Chronic Fatigue Syndrome:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MT-CO3 NC_012920.1:m.9355A>T SNV Uncertain Significance
523307 rs1556423663 GRCh37: MT:9355-9355
GRCh38: MT:9355-9355

Expression for Chronic Fatigue Syndrome

Search GEO for disease gene expression data for Chronic Fatigue Syndrome.

Pathways for Chronic Fatigue Syndrome

Pathways related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1 13.61 ADCYAP1 CRH HTR1A IGF1 IGF2 IL2
2
Show member pathways
13.49 INS IL6 IL2 IGF2 IGF1 IFNG
3
Show member pathways
13.19 EIF2AK2 GH1 IFNG IL2 IL6 MAOA
4
Show member pathways
12.99 INS IL6 IL2 IGF2 IGF1 GH1
5
Show member pathways
12.87 INS IL6 IL2 IGF2 IGF1 GH1
6
Show member pathways
12.7 IFNG IGFBP1 IL2 NR3C1 SLC6A4
7
Show member pathways
12.57 IL6 IL2 IGF2 IGF1 GH1 EIF2AK2
8
Show member pathways
12.42 RNASEL IL6 IL2 IGF2 IGF1 IFNG
9
Show member pathways
12.34 IL6 IL2 IGF2 IGF1 GH1
10
Show member pathways
12.33 IGF1 IGF2 IGFBP1 IL6
11
Show member pathways
12.14 POMC INS IGF1 GH1
12
Show member pathways
12.1 VIP POMC CRH ADCYAP1
13
Show member pathways
12.05 IGFBP1 INS NR3C1 POMC
14 11.84 INS IL6 IGF1
15 11.82 POMC IL2 CRH
16 11.77 NR3C1 INS IL6 IGF1 GH1
17 11.72 IL6 IL2 IFNG
18 11.71 IL6 IL2 IFNG
19 11.69 IL6 IL2 IFNG
20 11.67 IL6 IL2 IFNG
21 11.66 IL6 IL2 IGF2 IGF1 GH1
22
Show member pathways
11.58 IL6 IL2 IFNG
23 11.57 NR3C1 IL6 IL2 IFNG
24 11.57 RNASEL INS IL6 IGF1 IFNG
25 11.56 INS IL6 IFNG
26 11.53 IL6 IL2 IFNG
27 11.52 IGF1 IGF2 INS
28
Show member pathways
11.5 NR3C1 IL6 IL2 IFNG
29 11.46 INS IL6 IGF1
30
Show member pathways
11.4 NR3C1 INS IGFBP1
31 11.3 SLC6A4 NR3C1 MAOA IL6 HTR1A ADCYAP1
32 11.28 IFNG IGF1 IL6 NR3C1
33 11.24 POMC NR3C1 IL6 IL2 IFNG
34
Show member pathways
11.2 POMC HTR1A CRH
35 11.19 IL6 IL2 IFNG
36 11.16 SLC6A4 MAOA HTR1A
37 11.13 IL6 IL2 IFNG
38
Show member pathways
11.03 SLC6A4 MAOA HTR1A
39 10.98 IL6 IL2 IGF2 IGF1 GH1
40 10.68 IL2 IFNG
41 10.68 IL6 IL2
42 10.49 POMC CRH

GO Terms for Chronic Fatigue Syndrome

Cellular components related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.98 POMC MIR146A INS IL6 IL2 IGFBP1
2 extracellular region GO:0005576 9.7 ADCYAP1 CRH GH1 IFNG IGF1 IGF2

Biological processes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.37 POMC NR3C1 INS IL6 IGFBP1 IGF1
2 positive regulation of gene expression GO:0010628 10.1 SLC6A4 MIR146A INS IL6 IGF1 IFNG
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 10.01 IL6 IGF2 IGF1 GH1
4 positive regulation of chemokine production GO:0032722 9.99 IL6 IFNG EIF2AK2
5 positive regulation of MAPK cascade GO:0043410 9.96 INS IL6 IGF2 IGF1 EIF2AK2
6 positive regulation of glucose import GO:0046326 9.95 IGF1 INS RNASEL
7 positive regulation of mitotic nuclear division GO:0045840 9.93 INS IGF2 IGF1
8 positive regulation of activated T cell proliferation GO:0042104 9.91 IL2 IGF2 IGF1
9 positive regulation of cell population proliferation GO:0008284 9.86 VIP INS IL6 IL2 IGF2 IGF1
10 positive regulation of glycolytic process GO:0045821 9.85 IFNG IGF1 INS
11 neuroinflammatory response GO:0150076 9.7 NR3C1 IFNG
12 positive regulation of glycogen biosynthetic process GO:0045725 9.63 IGF1 IGF2 INS
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.32 IL6 IL2 IGF1 IFNG GH1

Molecular functions related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.85 GH1 IGF1 IGF2 IL2 IL6
2 neuropeptide hormone activity GO:0005184 9.8 VIP CRH ADCYAP1
3 insulin receptor binding GO:0005158 9.73 INS IGF2 IGF1
4 hormone activity GO:0005179 9.5 VIP POMC INS IGF2 IGF1 GH1
5 insulin-like growth factor receptor binding GO:0005159 9.43 INS IGF2 IGF1

Sources for Chronic Fatigue Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....